Live Salesforce, Inc. Vote →

Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies
Get started →
Sign up to stay up to date with the stocks you care about
Follow Prelude Therapeutics Inc

Get SEC filing alerts via email and in your feed for Prelude Therapeutics Inc

PRLD

Prelude Therapeutics Inc

About Prelude Therapeutics Inc

Prelude Therapeutics is a clinical-stage oncology company focused on developing precision cancer medicines targeting underserved patient populations. Its pipeline includes targeted degraders, antibody drug conjugates, and kinase inhibitors designed to address high unmet medical needs. The company leverages expertise in cancer biology and medicinal chemistry to discover and advance novel, highly selective therapies through efficient clinical development and regulatory pathways.
This description was generated via AI from an annual report. Updated 8 months ago.

Latest SEC Filings from Prelude Therapeutics Inc

1
1
Prelude Therapeutics Inc Prelude Therapeutics Reports $4.58 Million Revenue in Q1 2026, Net Loss Improves to $10.39 Million

Via official filing (AI summary) | 23 days ago | 0 comments

2
1
Prelude Therapeutics Inc Prelude Therapeutics Reports $99.5M Net Loss, Pauses SMARCA2 Program

Via official filing (AI summary) | 3 months ago | 0 comments

3
1
Prelude Therapeutics Inc Prelude Therapeutics Reports Revenue Increase and Reduced Losses in Q3 2025

Via official filing (AI summary) | 7 months ago | 0 comments

4
1
Prelude Therapeutics Inc Prelude Therapeutics Reports $31.2 Million Net Loss in Q2 2025, Seeks Additional Funding

Via official filing (AI summary) | 10 months ago | 0 comments

5
1
Prelude Therapeutics Inc Prelude Therapeutics Reports Q1 2025 Financial Results with Increased Net Loss and Cash Reserves

Via official filing (AI summary) | about 1 year ago | 0 comments

6
1
Prelude Therapeutics Inc Prelude Therapeutics Reports $127.2 Million Net Loss for 2024, Highlights Clinical Trial Developments

Via official filing (AI summary) | about 1 year ago | 0 comments

7
1
Prelude Therapeutics Inc Prelude Therapeutics Reports First Revenue, Increased Expenses, and Net Loss in Q3 2024

Via official filing (AI summary) | over 1 year ago | 0 comments